文献速递甲状腺核医学核素与放射性配体治疗

重组人促甲状腺激素与甲状腺激素撤退在Intermediate- to High-Risk甲状腺癌131I治疗中的比较:系统综述与Meta分析

Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131 I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer : A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Nucl Med · 2024-01-19

该Meta分析纳入13项研究共1858例intermediate- to high-risk分化型甲状腺癌患者,比较rhTSH与THW用于RAI治疗的疗效;总体RRA成功率的RR为1.12(95%CI 1.01-1.25),但高危亚组RRA成功率无显著差异(RR 1.05,95%CI 0.88-1.24),远处转移患者疾病控制率亦无显著差异(RR 1.06,95%CI 0.78-1.44);作者认为rhTSH是实用选择。

要点

  • 总体RRA成功率rhTSH组高于THW组,RR 1.12(95%CI 1.01-1.25)。高危亚组RRA成功率两组无显著差异,RR 1.05(95%CI 0.88-1.24)。
  • 远处转移患者疾病控制率两组无显著差异,RR 1.06(95%CI 0.78-1.44)。
  • 作者认为rhTSH用于intermediate- to high-risk甲状腺癌RAI治疗是实用选择,包括远处转移患者。

核心结论

  • 作者认为rhTSH用于intermediate- to high-risk甲状腺癌患者的RAI治疗是实用选择,包括远处转移患者。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE和Cochrane数据库2012年1月至2023年6月发表的比较rhTSH与THW在intermediate- to high-risk分化型甲状腺癌中临床结局的文章。
  • Meta分析纳入13项研究共1858例患者,PROSPERO注册号CRD42022340915。

主要发现

  • 总体RRA成功率的汇总分析显示rhTSH组显著高于THW组,RR 1.12(95%CI 1.01-1.25)。
  • 高危患者亚组分析中,rhTSH组与THW组RRA成功率无显著差异,汇总RR 1.05(95%CI 0.88-1.24)。
  • 远处转移患者中,两组疾病控制率无显著差异,汇总RR 1.06(95%CI 0.78-1.44),疾病控制率采用RECIST标准评估。

关键数值与推荐

  • RRA成功率总体汇总RR 1.12(95%CI 1.01-1.25),rhTSH组高于THW组。
  • 高危亚组RRA成功率汇总RR 1.05(95%CI 0.88-1.24),两组无显著差异。
  • 远处转移患者疾病控制率汇总RR 1.06(95%CI 0.78-1.44),两组无显著差异。

临床怎么用

  • 作者认为rhTSH用于intermediate- to high-risk甲状腺癌患者的RAI治疗是实用选择,包括远处转移患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This meta-analysis and systematic review aimed to evaluate the therapeutic efficacy and advantages associated with the use of recombinant human thyroid-stimulating hormone (rhTSH) for radioactive iodine (RAI) therapy in patients with intermediate- to high-risk differentiated thyroid cancer. PATIENTS AND METHODS: MEDLINE, EMBASE, and Cochrane databases were searched to identify relevant articles reporting clinical outcomes of rhTSH compared with thyroid hormone withdrawal (THW) in patients with intermediate- to high-risk differentiated thyroid cancer published between January 2012 and June 2023. Meta-analyses were performed (PROSPERO registration number: CRD42022340915) to assess the success rate of radioiodine remnant ablation (RRA) in patients with intermediate to high risk and determine the disease control rate among patients with distant metastases, evaluated using the RECIST criteria. RESULTS: Thirteen studies involving 1858 patients were included in the meta-analysis. Pooled analyses revealed significantly higher overall RRA success rate in the rhTSH group compared with the THW group, with a risk ratio (RR) of 1.12 (95% confidence interval [CI], 1.01-1.25). However, in the subgroup analysis of high-risk patients, pooled analyses showed no significant differences in RRA success rate between the rhTSH group compared with the THW group with a pooled RR of 1.05 (95% CI, 0.88-1.24). In patients with distant metastases, there were no significant differences in the disease control rate between groups, with a pooled RR of 1.06 (95% CI, 0.78-1.44). CONCLUSIONS: rhTSH for RAI therapy is a practical option for RAI therapy in patients with intermediate- to high-risk thyroid cancer, including those with distant metastases.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Park S, Bang JI, Kim K, et al. Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131 I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer : A Systematic Review and Meta-analysis. Clin Nucl Med. 2024. PMID: 38271262. doi:10.1097/RLU.0000000000005022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。